Lerodalcibep (Lerochol)

What clinical trials found

PCSK9 inhibitor (third-generation, small recombinant fusion protein)

Once-monthly, self-administered injection, room-temperature stable for up to 3 months (most PCSK9 injectables need refrigeration). FDA-approved December 2025 for hypercholesterolemia including heterozygous FH, launched in the US in spring 2026 as a prefilled syringe, with an autoinjector following later in the year. A direct-to-patient cash program is available at $199/month.